Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis

Taisuke Yatomi1, Takahito Uchida1,2, Akihiro Takamiya1, Masataka Wada1, Shun Kudo1, Kazuki Nakajima1, Hana Nishida1, Bun Yamagata1, Masaru Mimura1 and Jinichi Hirano*1

1 Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan, 2 Department of Psychiatry, Melbourne Neuropsychiatry Centre, The University of Melbourne, Parkville, VIC, Australia

OBJECTIVE: Although anesthetics play an important role in electroconvulsive therapy (ECT), the clinical efficacy and seizure adequacy of sevoflurane in the course of ECT remain unclear. The purpose of this study was to examine the clinical efficacy and seizure adequacy of sevoflurane, compared with those of thiopental, in the course of ECT in patients with mood disorders.

METHODS: We conducted a retrospective chart review. Patients who underwent a course of ECT and received sevoflurane (n = 26) or thiopental (n = 26) were included. Factors associated with ECT and treatment outcomes were compared between the two groups using propensity score (PS) matching. Between-group differences were examined using an independent t-test for continuous variables and a χ²-test for categorical variables.

RESULTS: Patients who received sevoflurane needed more stimulations (sevoflurane: 13.2 ± 4 times, thiopental: 10.0 ± 2.5 times, df = 51, p = 0.001) and sessions (sevoflurane: 10.0 ± 2.1 times, thiopental: 8.4 ± 2.1 times, df = 51, p = 0.01) and had more inadequate seizures (sevoflurane: 5 ± 3.9 times, thiopental: 2.7 ± 2.7 times, df = 51, p = 0.015). Remission and response rates were similar in both groups.

CONCLUSION: The present findings indicate that sevoflurane should be used with caution in ECT and only when the clinical rationale is clear.

Keywords: anesthesia, electroconvulsive therapy, depression, sevoflurane, thiopental

INTRODUCTION

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder and a leading cause of disability worldwide (Vigo et al., 2016). Despite a range of pharmacological treatments, 30% of patients show poor response (Rush et al., 2006) and are referred to as having treatment-resistant MDD. This group of patients may benefit from electroconvulsive therapy (ECT).
(Weiss et al., 2019). ECT requires general anesthesia (Weiss et al., 2019), which affects seizure adequacy that may contribute to the clinical efficacy and tolerability of ECT (Kadiyala and Kadiyala, 2017). Intravenous anesthesia is commonly used in ECT. However, inhalational anesthesia would be preferable, specifically for patients with needle phobia, poor tolerance of intravenous induction agents, and agitation that affects their ability to cooperate (Rasmussen et al., 2005; Bryson et al., 2017; Erdil et al., 2017). Sevoflurane is the most common inhalational anesthetic used in ECT (Bryson et al., 2017; Aoki et al., 2021) because of its rapid and smooth induction (Loughnan et al., 2004). In addition, higher doses of sevoflurane may induce epileptiform electroencephalogram (EEG) (Gibert et al., 2012), which may improve seizure adequacy. Meanwhile, sevoflurane increases the expression level of gamma-aminobutyric acid-A receptors in the brain (Murao et al., 2002) and shortens seizure duration induced by ECT (Rasmussen et al., 2006; Aoki et al., 2021). These factors may negatively affect seizure adequacy. Previous studies have investigated the effect of sevoflurane on ECT using a crossover design (Calarge et al., 2003; Wajima et al., 2003; Hodgson et al., 2004; Loughnan et al., 2004; Rasmussen et al., 2005, 2006, 2007; Toprak et al., 2005; Matsubara et al., 2012; Begeç et al., 2013; Jadeja et al., 2014; Ulusoy et al., 2014; Erdil et al., 2015a,b, 2017; Pekel et al., 2016; Aoki et al., 2021). However, to the best of our knowledge, no previous study has investigated the effects of sevoflurane used throughout the course of ECT (i.e., when sevoflurane was used in all sessions of the course of ECT).

At our institution, intravenous anesthesia using thiopental (Nuzzi et al., 2018; Weiss et al., 2019) has been the standard protocol for ECT. However, sevoflurane is becoming increasingly popular as a standard because it facilitates rapid and smooth anesthesia induction. Therefore, we were able to compare the efficacy and outcomes associated with both anesthetics with minimal selection bias. This study aimed to examine the outcomes of sevoflurane used throughout the course of ECT, including seizure adequacy, and to compare them to those of thiopental use, using propensity score (PS) matching.

MATERIALS AND METHODS

The data used in this study included a retrospectively collected dataset from the Keio Neuropsychiatry ECT Database. Therefore, informed consent was not required from the patients. The database includes patients who received ECT for an MDD episode at the Keio University Hospital, Tokyo, Japan. This study included patients undergoing treatment between April 2012 and March 2019. This study was approved by the Ethics Committee of the Keio University School of Medicine and adhered to the tenets of the Declaration of Helsinki.

Eligibility Criteria

Patients were included in this study if they received ECT for an MDD episode (including bipolar depression) at the Keio University Hospital, had a diagnosis of MDD or bipolar disorder based on the Diagnostic Statistical Manual of Mental Disorders (DSM) IV-TR or DSM-5, and received thiopental or sevoflurane for general anesthesia during ECT. To ensure the validity of the diagnosis, more than two psychiatrists (AT, TU, and HJ) evaluated the diagnosis of all the cases retrospectively. If the same patient underwent more than one course of ECT during the study period, the data from the first ECT course were used for the analysis.

Patients were excluded from this study if the anesthetic agent was changed over the course of ECT and if they underwent fewer than five ECT sessions.

Participant Characteristics

Data on the participants’ demographic and clinical characteristics were extracted from our database, including age, sex, diagnosis, years of education, age at diagnosis, number of episodes, height, and weight.

Clinical Assessments

The baseline severity of MDD was assessed using the Clinical Global Impression–Severity scale (CGI-S). The CGI-S is a seven-point scale, where a score of 1 point indicates a normal state and a score of 7 points indicates severe illness (Guy, 1976). In addition, psychotic, melancholic, and catatonic features, as defined by DSM IV-TR or DSM-5, were assessed at baseline.

Response to ECT was assessed using the clinical note Global Impression Improvement scale (c-CGI) (Kaster et al., 2017), which is a 4-point scale, where 1 point indicates excellent response and 4 points indicate poor response. This scale has been used in previous retrospective ECT chart reviews (Kristensen et al., 2013; Kaster et al., 2017). Three board-certified psychiatrists (AT, TU, and HJ) retrospectively assessed the CGI scores and other clinical features based on medical records; the assessors were blinded to the type of anesthetic used; any disagreements were resolved by discussion. Remission was defined as a c-CGI score of 1 point, and treatment response was defined as a c-CGI score of 1 or 2 points; therefore, patients who met the remission criteria also met the response criteria.

Drug Dosage

The Anatomical Therapeutic Chemical (ATC) classification system and Defined Daily Dose (DDD) are recommended by the World Health Organization as measuring units for drug utilization studies. Based on the ATC classification, we identified hypnotics (ATC code: N05C), antidepressants (ATC code: N06A), anxiolytics (ATC code: N05B), antipsychotics (ATC code: N05A), anti-epileptics (ATC code: N03), and mood stabilizers (ATC code: N05AN). DDD is defined as an assumed average daily maintenance dose of a drug in a typical adult. When a patient receives two or more drugs, a summed DDD value is calculated per category.

Electroconvulsive Therapy Protocol and Associated Factors

At our hospital, modified brief-pulse (0.5 ms) ECT (Thymatron system IV devices; Somatics, Inc., Lake Bluff, Ill) was used.
administered twice or thrice weekly to inpatients. Bitemporal ECT using the half-age method was selected for all patients during the study period. When the initial stimulation did not cause adequate seizures based on the clinical judgment of the attending psychiatrist, the stimulation intensity was increased, and the patient received up to three more stimulations.

Treatment duration was determined by the clinical outcome and possible adverse events (Weiss et al., 2019). Specifically, ECT sessions were continued until symptomatic improvement reached a plateau, and when the last two sessions did not yield any further improvement according to the judgment of the psychiatrist-in-charge.

The following ECT-related factors were evaluated: number of ECT sessions per course (referred to as “number of ECT sessions”), number of stimulations per ECT course (referred to as “number of ECT stimulations”), charge used at the last ECT session, average charge used for ECT stimulations, average post-ictal suppression index, average seizure length, and number of inadequate seizures (defined as a seizure lasting < 20 s on EEG).

**Choice of Anesthetic**
Sodium thiopental (3–5 mg/kg) or sevoflurane (8%) was used for general anesthesia, and succinylcholine (0.5–1.0 mg/kg) was used to induce muscle relaxation. The choice of anesthetic was determined by the attending anesthetists based on clinical standards (thiopental before 2016 and sevoflurane thereafter).

**Data Analysis**
Participants’ characteristics were reported as descriptive statistics. Patients were divided into the sevoflurane and thiopental groups, and between-group differences were examined using an independent t-test for continuous variables and a $\chi^2$-test for categorical variables. All analyses were two-sided with an $\alpha$-level set at 0.05. Data were analyzed using R Version 3.4.3.

**Propensity Score Matching**
To control for confounding factors, we used PS matching analysis. PS matching reduces bias due to confounding factors by matching patients on baseline variables using a multivariable logistic regression model. PS matching was performed on the following factors: weight, height, and medications (DDD values of hypnotics, antidepressants, anxiolytics, antipsychotics, antiepileptics, and mood stabilizers), diagnosis of MDD or bipolar disorder (Bahji et al., 2019), CGI scores (van Diermen et al., 2018), presence of psychotic symptoms (van Diermen et al., 2018), and demographic characteristics such as age (van Diermen et al., 2018) and sex. PS-matched pairs were created at a ratio of 1:1 based on the nearest neighbor matching algorithm with a 0.20-caliper distance with no replacements. The goodness-of-fit of the logistic regression model was evaluated by the area under the curve. All PS matching procedures were conducted using the Matching package in R version 3.4.3.

**RESULTS**
Among 186 patients with MDD included in the database, 83 received sevoflurane or thiopental for all ECT sessions and were included in the present analysis. A total of 52 patients (26 patients per group) were compared using PS matching (Figure 1).

**Participant Demographics and Clinical Characteristics**
Demographic and clinical characteristics of the overall sample are presented in Table 1. A total of 37 and 46 patients were
TABLE 1 | Participant characteristics before propensity score matching.

|                          | Sevoflurane (n = 37) | Thioptental (n = 46) | SMD         | p        |
|--------------------------|----------------------|----------------------|-------------|----------|
| Age (years)              | 63.32 ± 14.46        | 61.65 ± 14.14        | 0.117       | 0.597    |
| Sex, males n (%)         | 16 (43.2)            | 18 (39.1)            | 0.084       | 0.877    |
| Diagnosis, MDD n (%)     | 32 (86.5)            | 37 (80.4)            | 0.163       | 0.662    |
| Education years (years)  | 14.51 ± 2.1          | 13.83 ± 2.51         | 0.197       | 0.377    |
| Onset age (years)        | 55.89 ± 17.64        | 52.39 ± 17.98        | 0.231       | 0.315    |
| Duration of disease (months) | 80.49 ± 98        | 105.72 ± 123.88      | 0.115       | 0.601    |
| Number of episodes (times) | 2.41 ± 1.82        | 2.59 ± 2.77          | 0.171       | 0.732    |
| Duration of the current episode (months) | 16.12 ± 44.67 | 20.83 ± 36.93        | 0.073       | 0.738    |
| Psychotic symptoms, n (%) | 13 (35.1)          | 20 (43.5)            | 0.171       | 0.585    |
| Height (cm)              | 160.75 ± 9.6         | 160.1 ± 8.15         | 0.016       | 0.941    |
| Weight (kg)              | 52.9 ± 12.81         | 52.69 ± 12.42        | 0.016       | 0.941    |
| Number of ECT sessions (times) | 9.59 ± 2.35        | 8.96 ± 2.17          | 0.016       | 0.941    |
| Number of total stimulation (times) | 12.89 ± 3.97   | 10.78 ± 2.82         | 0.016       | 0.941    |
| Inadequate seizures (times) | 5.16 ± 4.26        | 2.93 ± 2.9           | 0.016       | 0.941    |
| Last ECT charge (mc)     | 361.67 ± 134.42      | 337.13 ± 136.08      | 0.016       | 0.941    |
| Average ECT charge (mc)  | 295.95 ± 109.97      | 247.92 ± 84.57       | 0.016       | 0.941    |
| Average ECT GTC seizures (seconds) | 43.33 ± 10.16 | 44.31 ± 8.69         | 0.016       | 0.941    |
| Average ECT PSI (%)      | 74.72 ± 11.72        | 78.75 ± 11.9         | 0.016       | 0.941    |
| Antidepressants (DDD)    | 1.11 ± 0.83          | 0.9 ± 0.94           | 0.016       | 0.941    |
| Antipsychotics (DDD)     | 0.2 ± 0.27           | 0.34 ± 0.43          | 0.39        | 0.088    |
| Anxiolytics (DDD)        | 0.06 ± 0.23          | 0.07 ± 0.26          | 0.044       | 0.845    |
| Hypnotics (DDD)          | 0.78 ± 0.73          | 0.61 ± 0.83          | 0.219       | 0.328    |
| Anti-epileptic drug (DDD) | 0 ± 0.01           | 0.01 ± 0.06          | 0.305       | 0.192    |
| Mood stabilizer (DDD)    | 0 ± 0               | 0.1 ± 0.71           | 0.209       | 0.373    |
| Pre CGI-7                | 4.84 ± 1.21          | 4.63 ± 1.36          | 0.161       | 0.47     |
| Post CGI                 | 1.56 ± 0.89          | 1.78 ± 1             | 0.316       | 0.316    |
| CGI remission, n (%)     | 22 (64.7)            | 24 (53.3)            | 0.433       | 0.433    |
| CGI response, n (%)      | 29 (85.3)            | 35 (77.8)            | 0.58        | 0.58     |

Values are expressed as mean ± SD unless otherwise indicated. The between-group differences were examined using the independent t-test for continuous variables and the χ²-test for categorical variables.

SMD, Standardized Mean Difference; MDD, major depressive disorder; ECT, electroconvulsive therapy; GTC, generalized tonic-clonic seizures; PSI, Post-Ictal Suppression index; DDD, defined daily dose; CGI, Clinical Global Impressions. *p < 0.05, **p < 0.01.

Results of Propensity Score-Matched Analysis

Although the area under the receiver operating characteristic curve was 0.696 (95% confidence interval: 0.582–0.811) (Figures 2, 3), PS matching showed that the distribution of PS was well matched in the study. Demographic and clinical characteristics were similar between the PS-matched sevoflurane and thiopental groups. The sevoflurane group required more ECT stimulations (sevoflurane: 13.2 ± 4.0 times, thiopental: 10.0 ± 2.5 times, df = 51, p = 0.001), more ECT sessions (sevoflurane: 10.0 ± 2.1 times, thiopental: 8.4 ± 2.1 times, df = 51, p = 0.01), and experienced more inadequate seizures (sevoflurane: 5.0 ± 3.9 times, thiopental: 2.7 ± 2.7 times, df = 51, p = 0.015) than the thiopental group. The characteristics of the PS-matched participants are presented in Table 2.

DISCUSSION

This study examined the clinical efficacy and seizure adequacy associated with ECT in patients with MDD who received sevoflurane or thiopental throughout the ECT course. In the present study, the number of stimulations, ECT sessions, and inadequate seizures were significantly higher in the sevoflurane group than in the thiopental group. These findings suggest some disadvantages of the routine use of sevoflurane as a general anesthetic for ECT.
ECT is a treatment option for the most severe psychiatric disorders, making it difficult to conduct a randomized controlled trial on the impact of the anesthetic type used during treatment administration (Fond et al., 2016); consequently, we used PS matching in this study. Previous studies on the use of sevoflurane in ECT involved crossover or parallel randomized designs (Calarge et al., 2003; Wajima et al., 2003; Hodgson et al., 2004; Loughnan et al., 2004; Toprak et al., 2005; Rasmussen et al., 2006, 2007; Matsubara et al., 2012; Begeç et al., 2013; Jadeja et al., 2014; Ulusoy et al., 2014; Erdil et al., 2015a,b, 2017; Pekel et al., 2016; Aoki et al., 2021). To the best of our knowledge, this is the first study to investigate the impact of sevoflurane used during the entire treatment course on the clinical efficacy and seizure adequacy of ECT. This study involved a proper evaluation of matching (Ali et al., 2015), and the distribution of PS overlapped between the groups and covariates was balanced (Bergstra et al., 2019).

Aoki et al. (2021) performed a meta-analysis showing that sevoflurane shortened seizure duration and increased heart rate compared with other intravenous anesthetics. In addition, previous cross-over studies on the clinical effects of sevoflurane and thiopental (Rasmussen et al., 2006; Jadeja et al., 2014) showed that sevoflurane shortened seizure duration compared with thiopental. Although the duration of seizures was similar in the sevoflurane and thiopental groups in the present study, the frequency of inadequate seizures was higher in the sevoflurane group than in the thiopental group. The increase in the number of inadequate seizures associated with sevoflurane may have clinical implications. In fact, in our dataset, the sevoflurane group received more ECT sessions and ECT stimulations than the thiopental group. These increases may result in increased hospitalization duration and financial burden to both patients and healthcare systems. Furthermore, the number of stimulations has been associated with the risk of delirium (Tsujii et al., 2019), which is an adverse neuropsychological event. A previous study showed that the number of treatments was relevant to cognitive decline in specific cognitive domains such as autobiographical memory (Sackeim et al., 2007; Porter et al., 2008). Relevant to this evidence, increasing the number of treatments in the sevoflurane group may exacerbate cognitive decline caused by ECT.
### TABLE 2 | Participant characteristics after propensity score matching.

|                  | Sevoflurane (n = 26) | Thiopental (n = 26) | SMD (95% CI) | p |
|------------------|-----------------------|---------------------|--------------|---|
| Age (years)      | 63.31 ± 13.64         | 63.46 ± 13.78       | 0.011 ± 0.968|   |
| Sex, males n (%) | 11 (42.3)             | 10 (38.5)           | 0.078 ± 1    |   |
| Diagnosis, MDD n (%) | 21 (80.8)     | 23 (88.5)           | 0.214 ± 0.701|   |
| Education years | 14.42 ± 2.16          | 14.04 ± 2.57        | 0.561 ± 0.67 |   |
| Onset age (years) | 55 ± 17.98           | 52.77 ± 19.57       | 0.119 ± 0.67 |   |
| Duration of disease (months) | 87.62 ± 102.19 | 115.38 ± 144.14    | 0.427 ± 0.59 |   |
| Number of episodes (times) | 2.62 ± 1.96       | 2.31 ± 1.81        | 0.059 ± 1    |   |
| Duration of current episode (months) | 9.04 ± 8.27        | 25.85 ± 42.59      | 0.548 ± 0.054|   |
| Psychotic symptoms, n (%) | 9 (34.6)         | 10 (38.5)          | 0.08 ± 1    |   |
| Height (cm)      | 160.47 ± 9.79         | 160.72 ± 9.31       | 0.026 ± 0.925|   |
| Weight (kg)      | 51.62 ± 12.84         | 53.07 ± 13.5        | 0.11 ± 0.694 |   |
| Number of ECT sessions (times) | 9.96 ± 2.09       | 8.42 ± 2.06        | 0.01** ± 0.01**|   |
| Number of total stimulation (times) | 13.19 ± 4         | 10.04 ± 2.54       | 0.001** ± 0.001**|   |
| Inadequate seizures (times) | 5 ± 3.93          | 2.65 ± 2.67        | 0.015* ± 0.015*|   |
| Last ECT charge (mc) | 360.56 ± 140.92 | 325.68 ± 120.96    | 0.343 ± 0.112 |   |
| Average ECT charge (mc) | 296.7 ± 45.12 | 252.7 ± 79.18      | 0.581 ± 0.112 |   |
| Average ECT GTC seizures (seconds) | 42.43 ± 8.24 | 43.64 ± 7.38       | 0.15 ± 0.15 |   |
| Average ECT PSI (%) | 75.39 ± 12.23 | 80.08 ± 10.2       | 0.15 ± 0.15 |   |
| Antidepressants (DDD) | 1.1 ± 0.9           | 0.9 ± 0.96         | 0.22 ± 0.431 |   |
| Antipsychotics (DDD) | 0.23 ± 0.3          | 0.16 ± 0.25        | 0.251 ± 0.369 |   |
| Anxiolytics (DDD)  | 0.05 ± 0.24          | 0.11 ± 0.33        | 0.219 ± 0.433 |   |
| Hypnotics (DDD)   | 0.66 ± 0.73          | 0.65 ± 0.87        | 0.016 ± 0.955 |   |
| Anti-epileptic drug (DDD) | 0 ± 0.01         | 0 ± 0             | 0.277 ± 0.322 |   |
| Mood stabilizer (DDD) | 0 ± 0              | 0 ± 0             | < 0.001 NaN |   |
| Pre CGI-7         | 4.81 ± 1.2           | 4.5 ± 1.48         | 0.229 ± 0.414 |   |
| Post CGI          | 1.6 ± 0.96           | 1.65 ± 0.89        | 0.836 ± 1    |   |
| CGI remission, n (%) | 16 (64.0)         | 15 (57.7)          | 0.862 ± 1    |   |
| CGI response, n (%) | 21 (84.0)         | 21 (80.8)          | 1 ± 1        |   |

Values are expressed as mean ± SD unless otherwise indicated. The between-group differences were examined using an independent t-test for continuous variables and a χ²-test for categorical variables.

SMD, Standardized Mean Difference; MDD, major depressive disorder; ECT, electroconvulsive therapy; GTC, generalized tonic-clonic seizures; PSI, Post-ictal Suppression Index; DDD, defined daily dose; CGI, Clinical Global Impressions; NaN.

* p < 0.05, ** p < 0.01, *** p < 0.005.

Moreover, ECT causes generalized autonomic nervous system response, with initial parasympathetic-induced bradycardia followed immediately by a sympathetic response that results in transient tachycardia and hypertension (Ding and White, 2002; Uppal et al., 2010) and myocardial oxygen consumption increases (Ding and White, 2002; Uppal et al., 2010). An increased number of sessions may increase the occurrence of arrhythmias and cardiac overloads, which may be problematic, particularly in older adults.

In the present study, the sevoflurane and thiopental groups achieved similar treatment outcomes; this finding is consistent with that of a previous study (Fond et al., 2016), which concluded that the evidence to recommend a specific anesthetic for ECT is insufficient, and the choice should be at the discretion of the attending physician, given the adverse event profile and seizure duration. This approach makes room for the use of sevoflurane in this context (Andrade, 2021). Sevoflurane may be useful for patients who are agitated or afraid of injections (Rasmussen et al., 2005), experience problematic prolonged seizures (Andrade, 2021), and are pregnant, as this agent helps reduce uterine contractions after ECT (Ishikawa et al., 2001; Andrade, 2021).

This study had some limitations. First, data were collected retrospectively, including information on treatment outcomes. Specifically, the retrospective use of CGI-S and c-CGI may attenuate the reliability of treatment outcomes. Future research may need a structured assessment of symptoms. Second, the time interval between anesthetic and ECT administrations and depth of anesthesia were not evaluated; all of these factors may affect seizure quality (Kranaster et al., 2013; Gálvez et al., 2016; Gálvez and Loo, 2017; Taylor et al., 2019). Consequently, we could not exclude the possibility that our results reflect differences in the depth of anesthesia rather than differences in the action of anesthetic agents. Third, we might not completely eliminate the other confounding factor that potentially affects the convulsion’s quality.
The present findings suggest potential disadvantages of sevoflurane for ECT, as it may increase the number of ECT stimulations and sessions required and that of inadequate seizures experienced by patients. The present findings suggest that sevoflurane for ECT should be used cautiously and only when the clinical rationale is clear.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because participants of this study did not consent to their data being shared publicly. Requests to access the datasets should be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the Keio University School of Medicine. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

Ali, M. S., Groenwold, R. H. H., Belitzer, S. V., Pestman, W. R., Hoes, A. W., Roos, K. C., et al. (2015). Reporting of covariate selection and balance assessment in propensity score analysis is Suboptimal: a systematic review. J. Clin. Epidemiol. 68, 112–121. doi: 10.1016/j.jclinepi.2014.08.011

Andrade, C. (2021). Anesthesia for electroconvulsive therapy: a niche role for sevoflurane. J. Clin. Psychiatry 82:21f14173. doi: 10.4088/JCP.21f14173

Aoki, N., Suwa, T., Kawashima, H., Tajioka, A., Sunada, N., Shimizu, T., et al. (2021). Sevoflurane in electroconvulsive therapy: a systematic review and meta-analysis of randomised trials. J. Psychiatriatr. Res. 141, 16–25.

Bahji, A., Hawken, E. R., Sephry, A. A., Cabrera, C. A., and Vazquez, G. (2019). ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr. Scand. 139, 214–226. doi: 10.1111/acps.12994

Begec, Z., Erdogan Kayhan, G., Toprak, H. I., Sahin, T., Konur, H., Colak, C., et al. (2013). Sevoflurane alone and propofol with or without remifentanil for electroconvulsive therapy-a randomised, crossover study. Anaesth. Intensive Care 41, 202–206.

Bergstrø, S. A., Sepriano, A., Ramiro, S., and Landewé, R. (2019). Three handy tips and a practical guide to improve your propensity score models. RMD Open 5:e000953. doi: 10.1136/rmdopen-2019-000953

Bryson, E. O., Aloyisi, A. S., Farber, K. G., and Kellner, C. H. (2017). Individualized anesthetic management for patients undergoing electroconvulsive therapy: a review of current practice. Anesth. Analg. 124, 1943–1956. doi: 10.1213/ANE.0000000000001873

Calarge, C. A., Crowe, R. R., Gergis, S. D., Arndt, S., and Fron, R. P. (2003). The comparative effects of sevoflurane and methohexitol for electroconvulsive therapy. J. ECT 19, 221–225.

Ding, Z., and White, P. F. (2002). Anesthesia for electroconvulsive therapy. Anesth. Analg. 94, 1351–1364.

Erdil, F., Begec, Z., Kayhan, G. E., Yoloso, S., Ersoy, M. O., and Durmush, M. (2015a). Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy. J. Anesth. 29, 180–185.

Erdil, F., Ozgul, U., Colak, C., Cumurcu, B., and Durmush, M. (2015b). Effect of the addition of ketamine to sevoflurane anesthesia on seizure duration in electroconvulsive therapy. J. ECT 31, 182–185.

AUTHOR CONTRIBUTIONS

TY, TU, and JH were involved in the analysis, design, and interpretation of the data, wrote the first draft of the manuscript, and supervised the entire project. TY, TU, AT, MW, SK, KN, HN, BY, MM, and JH contributed to the interpretation of the data. All authors contributed to the article and approved the final manuscript.

FUNDING

This work was supported by the Japan Agency for Medical Research and Development (Grant Nos. JP21dm0307102h0003 and 22dm0307102h0004) and JSPS KAKENHI (Grant Nos. 17K10315 and 21K07551).

ACKNOWLEDGMENTS

We thank A. Hamada, M. Inaoka, M. Isobe, S. Katayama, Y. Kikuchi, S. Kurose, N. Nitta, H. Oi, M. Sakuma, K. Sawada, Y. Shimomura, A. Shiomi, S. Takasu, M. Waki, R. Watanabe, and M. Kimura for data collection.

Erdil, F., Ozgul, U., Şanlı, M., Kayhan, G., Çolak, C., and Durmush, M. (2017). The effects of remifentanil on hemodynamic response attenuation after electroconvulsive therapy under sevoflurane anesthesia. J. ECT 33, 264–267. doi: 10.1097/YCT.0000000000000411

Fond, G., Bennabi, D., Haffen, E., Brunel, L., Micoulaud-Franchi, J.-A., Loundou, A., et al. (2016). A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression. Sci. Rep. 6:19847. doi: 10.1038/srep19847

Gálvez, V., and Loo, C. K. (2017). Clinical applicability of monitoring the time interval between anesthesia and electroconvulsive therapy. J. ECT 33, 4–6. doi: 10.1097/YCT.0000000000000384

Gálvez, V., Hadzi-Pavlovic, D., Wark, H., Harper, S., Leyden, J., and Loo, C. K. (2016). The anaesthetic-ECT time interval in electroconvulsive therapy practice–Is it time to time? Brain Stimul. 9, 72–77. doi: 10.1016/j.brs.2015.09.005

Gilbert, S., Sabourdin, N., Louvet, N., Moutard, M.-L., Piat, V., Guye, M.-L., et al. (2012). Epileptogenic effect of sevoflurane: determination of the minimal alveolar concentration of sevoflurane associated with major epileptic signs in children. Anesthesiology 117, 1253–1261. doi: 10.1097/ALN.0b013e318273e272

Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare.

Hodgson, R. E., Dawson, P., Hold, A. R., Rout, C. C., and Zuma, K. (2004). Anaesthesia for electroconvulsive therapy: a comparison of sevoflurane with propofol. Anaesth. Intensive Care 32, 241–245.

Ishikawa, T., Kawahara, S., Saito, T., Otsuka, H., Kemmotsu, O., Hirayama, E., et al. (2001). Anesthesia for electroconvulsive therapy during pregnancy—a case report. Masui 50, 991–997.

Jadeja, C., Jadiwala, R., Mangal, D., Gohil, D. M., and Chhaya, V. A. (2014). Comparative study of sevoflurane and sodium thiopentone in electroconvulsive therapy. Med. Sci. Monit. 2, 628–632.

Kadylara, P. K., and Kadyljia, L. D. (2017). Anaesthesia for electroconvulsive therapy: an overview with an update on its role in potentiating electroconvulsive therapy. Indian J. Anaesth. 61, 373–380.

Kaster, T. S., Daskalakis, Z. J., and Blumberger, D. M. (2017). Clinical effectiveness and cognitive impact of electroconvulsive therapy for schizophrenia: a large study.
Yatomi et al. Sevoflurane and Thiopental on ECT

retrospective study. J. Clin. Psychiatry 78, e383–e389. doi: 10.4088/JCP.16m10686

Kranaster, L., Hoyer, C., Janke, C., and Sartorius, A. (2013). Bispectral index monitoring and seizure quality optimization in electroconvulsive therapy. Pharmacopsychiatry 46, 147–150. doi: 10.1055/s-0032-1313748

Kristensen, D., Hageman, I., Bauer, J., Jørgensen, M. B., and Correll, C. U. (2013). Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J. ECT 29, 271–276. doi: 10.1097/YCT.0b013e31828b34f6

Loughnan, T., McKenzie, G., and Leong, S. (2004). Sevoflurane versus propofol for induction of anaesthesia for electroconvulsive therapy: a randomized crossover trial. Anaesth. Intensive Care 32, 236–240.

Matsubara, T., Hirotoshi, Y., and Yoshio, H. (2012). Anaesthesia for electroconvulsive therapy – comparison of propofol with sevoflurane. Masai 61, 733–737.

Murao, K., Shingiu, K., Miyamoto, E., Ikeda, S., Nakao, S.-I., Masuzawa, M., et al. (2002). Anticonvulsant effects of sevoflurane on amygdaloid kindling and bicuculline-induced seizures in cats: comparison with isoflurane and halothane. J. Anesth. 16, 34–43. doi: 10.1007/s540-002-8092-0

Nuzzi, M., Delmonte, D., Barbini, B., Pasin, L., Sottocorna, O., Casiraghi, G. M., et al. (2018). Thiopental is better than propofol for electroconvulsive therapy. Acta Biomed. 88, 450–456.

Pekel, M., Postaci, N. A., Ayaç, I., Karasu, D., Keleş, H., Şen, O., et al. (2016). Sevoflurane versus propofol for electroconvulsive therapy: effects on seizure parameters, anesthesia recovery, and the bispectral index. Turk. J. Med. Sci. 46, 756–763.

Porter, R. J., Heenan, H., and Reeves, J. (2008). Early effects of electroconvulsive therapy on cognitive function. J. ECT 24, 35–39.

Rasmussen, K. G., Laurila, D. R., Brady, B. M., Lewis, C. L., Niemeyer, K. D., Sun, N. M., et al. (2006). Seizure length with sevoflurane and thiopental for induction of general anesthesia in electroconvulsive therapy: a randomized double-blind trial. J. ECT 22, 240–242. doi: 10.1097/01.yct.0000244243.10167.b4

Rasmussen, K. G., Laurila, D. R., Brady, B. M., Lewis, C. L., Niemeyer, K. D., Sun, N. M., et al. (2007). Anesthesia outcomes in a randomized double-blind trial of sevoflurane and thiopental for induction of general anesthesia in electroconvulsive therapy. J. ECT 23, 236–238. doi: 10.1097/yct.0b013e318136e1b4

Rasmussen, K. G., Spackman, T. M., and Hooten, W. M. (2005). The clinical utility of inhalational anesthesia with sevoflurane in electroconvulsive therapy. J. ECT 21, 239–242. doi: 10.1097/01.yct.0000180469.30712.90

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1903–1917.

Sackeim, H. A., Prudic, J., Fuller, R., Keilp, J., Lavori, P. W., and Olsson, M. (2007). The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 32, 244–254.

Taylor, R., Hadzi-Pavlovic, D., Nikolin, S., Bull, M., Wark, H., Leyden, J., et al. (2019). The anaesthetic-ECT time interval with thiopentone-impact on seizure quality. J. Affect. Disord. 252, 135–140. doi: 10.1016/j.jad.2019.04.027

Toprak, H. I., Gedik, E., Begeç, Z., Oztürk, E., Kaya, B., and Ersoy, M. O. (2005). Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J. ECT 21, 108–110.

Tsuji, T., Uchida, T., Suzuki, T., Mimura, M., Hirano, J., and Uchida, H. (2019). Factors associated with delirium following electroconvulsive therapy: a systematic review. J. ECT 35, 279–287. doi: 10.1097/YCT.0000000000000606

Ulusoý, H., Cekic, B., Besir, A., Geze, S., Hocaoglu, C., and Aktogan, A. (2014). Sevoflurane/remifentanil versus propofol/remifentanil for electroconvulsive therapy: comparison of seizure duration and haemodynamic responses. J. Int. Med. Res. 42, 111–119. doi: 10.1177/0300060513509036

Uppal, V., Jonathan, D., and Macfarlane, A. (2010). Anaesthesia for electroconvulsive therapy. Contin. Educ. Anaesth. Crit. Care Pain 10, 192–196.

van Dienrmen, L., van den Ameele, S., Kamperman, A. M., Sabbe, B. C. G., Vermeulen, T., Schrijvers, D., et al. (2018). Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br. J. Psychiatry 212, 71–80.

Vigo, D., Thornicroft, G., and Atun, R. (2016). Estimating the true global burden of mental illness. Lancet Psychiatry 3, 171–178.

Wajima, Z., Shiga, T., Yoshikawa, T., Ogura, A., Inoue, T., and Ogawa, R. (2003). Propofol alone, sevoflurane alone, and combined propofol-sevoflurane anaesthesia in electroconvulsive therapy. Anaesth. Intensive Care 31, 396–400. doi: 10.1177/0310057X0303100408

Weiss, A., Hussain, S., Ng, B., Sarma, S., Tiller, J., Waite, S., et al. (2019). Royal Australian and New Zealand College of Psychiatrists Professional Practice Guidelines for the administration of electroconvulsive therapy. Aust. N. Z. J. Psychiatry 53, 609–623. doi: 10.1177/0004867419839139

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yatomi, Uchida, Takamiya, Wada, Kado, Nakajima, Nishida, Yamagata, Mimura and Hirano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.